BF Biosciences Limited
Condensed Interim Statement of Financial Position
As at 30 September 2025
Un-audited 30 September | Audited 30 June | Un-audited 30 September | Audited 30 June | ||
EQUITY AND LIABILITIES | 2025 | 2025 | ASSETS | 2025 | 2025 |
Share capital and reserves | Non-current assets | ||||
Authorized share capital | |||||
400,000,000 (30 June 2025: 400,000,000) ordinary | Property, plant and equipment | 4,303,630,850 | 4,306,291,784 | ||
shares of Rs. 3 each (30 June 2025: Rs. 3 each) | 1,200,000,000 | 1,200,000,000 | Long term deposits | 11,848,050 | 11,848,050 |
Issued, subscribed and paid up capital 265,000,002 265,000,002
Share premium 1,780,198,135 1,780,198,135
Unappropriated profit 2,776,287,467 2,616,766,032
4,821,485,604 4,661,964,169Intangibles 3,556,687 3,983,490
4,319,035,587 4,322,123,324Current assets
Non-current liabilities
Long term loans - secured Long term musharaka - secured Deferred grant
Deferred taxation
Stores, spare parts and loose tools Stock in trade
96,444,009 | 94,931,102 |
1,693,262,690 | 1,645,285,845 |
571,171,186 | 184,242,161 |
213,095,899 | 97,036,053 |
86,749,969 | 128,218,236 |
1,299,172,300 | 1,166,746,670 |
203,508,243 | 175,476,534 |
251,121,372 | 344,470,143 |
1,270,020,864 | 1,305,735,092 |
57,873,603 | 61,606,153 |
291,586,557 | 318,371,385 |
240,870,584 | 186,576,298 |
Trade debts
Loans and advances
Deposits, prepayments and other receivables
1,860,351,608 1,872,288,928 Short term investmentsAdvance income tax - net
Current liabilities Cash and bank balances
Current portion of:
317,193,908 | 314,020,402 |
14,738,567 | 14,029,074 |
110,934,915 | 114,108,421 |
1,413,106,867 | 1,116,096,032 |
35,411,419 | 20,150,923 |
147,047,101 | 29,362,548 |
13,291,266 | 16,509,571 |
Long term loans - secured
Long term musharaka - secured
Deferred grant
Trade and other payables Contract liabilities
Short term borrowings - secured
Mark-up accrued on borrowings
4,414,525,668 3,836,406,744 Contingencies and commitments 2,051,724,043 1,624,276,9718,733,561,255 8,158,530,068 8,733,561,255 8,158,530,068
Chief Executive Officer Chief Financial Officer DirectorBF Biosciences Limited
Condensed Interim Statement of Profit or Loss (Un-audited)
For the period ended 30 September 2025
First Quarter Ended
30 September | 30 September | ||
2025 | 2024 | ||
Revenue - net | 2,432,294,309 | 1,386,371,545 | |
Cost of goods sold | (1,393,964,059) | (822,538,648) | |
Gross profit | 1,038,330,250 | 563,832,897 | |
Administrative expenses | (39,852,708) | (11,916,088) | |
Selling and distribution expenses | (709,174,402) | (304,865,314) | |
Other expenses | (27,103,847) | (28,189,471) | |
Other income | 34,849,422 | 2,401,815 | |
Profit from operations | 297,048,715 | 221,263,839 | |
Finance cost Profit before income tax, final tax and | (26,387,010) | (35,028,094) | |
minimum tax differential | 270,661,705 | 186,235,745 | |
Minimum tax differential | (2,773,900) | (4,159,351) | |
Final tax | - | (488,651) | |
Profit before income tax | 267,887,805 | 181,587,743 | |
Income tax | (108,366,370) | (66,314,740) | |
Profit after taxation | 159,521,435 | 115,273,003 | |
Earnings per share - basic and diluted | 1.81 | 1.82 |
BF Biosciences Limited
Condensed Interim Statement of Comprehensive Income (Un-audited)
For the period ended 30 September 2025
First Quarter Ended 30 September 30 September 2025 2024 Profit after taxation 159,521,435 115,273,003Items that will not be subsequently reclassified to profit or loss
- -Other comprehensive income for the period
159,521,435 115,273,003 Total comprehensive income for the periodBF Biosciences Limited
Condensed Interim Statement of Changes in Equity (Un-audited)
For the period ended 30 September 2025
Share capital | Capital reserve | Revenue reserve | Total |
Share premium | Unappropriated profit |
Total comprehensive income for the period - - 115,273,003 115,273,003
Balance as at 30 September 2024 190,000,002 - 2,284,891,679 2,474,891,681 Balance as at 01 Jul 2025 265,000,002 1,780,198,135 2,616,766,032 4,661,964,169Total comprehensive income for the period - - 159,521,435 159,521,435
Balance as at 30 September 2025 - unaudited 265,000,002 1,780,198,135 2,776,287,467 4,821,485,604
BF Biosciences Limited
Condensed Interim Statement of Cash Flows (Un-audited)
For the period ended 30 September 2025
First Quarter EndedCash flow from operating activities | 30 September 2025 | 30 September 2024 |
Profit after taxation | 159,521,435 | 115,273,003 |
Adjustments for non-cash and other items: | ||
Depreciation on property, plant and equipment | 66,958,205 | 15,326,302 |
Gain on disposal of property, plant and equipment | (6,250) | - |
Amortization | 426,803 | 138,362 |
Finance cost | 26,387,010 | 35,028,094 |
Gain on re-measurement of short term investments to fair value | (29,790,774) | (2,030,740) |
Gain realized on sale of short term investments | (3,051,070) | - |
Profit on bank deposits | (1,637,056) | (364,023) |
Minimum tax | 2,773,900 | 4,159,351 |
Final tax | - | 488,651 |
Income tax | 108,366,370 | 66,314,740 |
Provision for Workers' Profit Participation Fund | 14,536,074 | 10,001,920 |
Provision for Central Research Fund | 2,936,581 | 2,020,590 |
Provision for Workers' Welfare Fund | 5,523,708 | 3,800,730 |
193,423,501 | 134,883,977 | |
Cash generated from operations before working capital changes | 352,944,936 | 250,156,980 |
Effect on cash flow due to working capital changes | ||
(Increase) / decrease in current assets | ||
Stores, spare parts and loose tools | (1,512,907) | (20,570,646) |
Stock in trade | (47,976,845) | (221,659,973) |
Trade debts | (386,929,025) | (270,321,482) |
Loans and advances - considered good | (116,059,846) | (36,972,630) |
Deposits, prepayments and other receivables | 41,468,267 | (117,736,523) |
(511,010,356) | (667,261,254) | |
Increase / (decrease) in current liabilities | ||
Trade and other payables | 274,014,472 | 474,622,983 |
Contract Liabilities | 15,260,496 | 15,982,750 |
289,274,968 | 490,605,733 | |
Cash generated from operations | 131,209,548 | 73,501,459 |
Income tax paid | (82,103,793) | (14,010,329) |
Minimum tax paid | (2,773,900) | (4,159,351) |
Final tax paid | - | (295,308) |
(84,877,693) | (18,464,988) | |
Net cash generated from operating activities | 46,331,855 | 55,036,471 |
Cash flow from investing activities | ||
Fixed capital expenditure incurred | (64,297,271) | (97,276,169) |
Proceeds from sale of property, plant and equipment | 6,250 | - |
Short term investments - net | (99,583,786) | - |
Increase in long term deposit | - | (3,000,000) |
Profit on bank deposits received | 1,637,056 | 364,023 |
Net cash used in investing activities | (162,237,751) | (99,912,146) |
Cash flow from financing activities | ||
Long term loan paid | (68,310,033) | (58,358,908) |
Long term musharaka received | - | 26,768,774 |
Long term musharaka paid | (3,023,057) | (2,956,872) |
Subscription money received against IPO | - | 1,651,999,762 |
Finance cost paid | (23,794,338) | (27,153,043) |
Net cash (used in) / generated from financing activities | (95,127,428) | 1,590,299,713 |
Net (decrease) / increase in cash and cash equivalents | (211,033,324) | 1,545,424,038 |
Cash and cash equivalents at the beginning of the period | 315,107,595 | (49,928,877) |
Cash and cash equivalents at the end of the period | 104,074,271 | 1,495,495,161 |
Cash and cash equivalents comprise of the following: | ||
Cash and bank balances | 251,121,372 | 1,863,827,812 |
Short term borrowings - secured | (147,047,101) | (368,332,651) |
104,074,271 | 1,495,495,161 |